雄异恶唑 | 360-66-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 雄异恶唑
• 中文别名: 雄异唑；雄异噁唑
• 英文名称: androisoxazole
• 英文别名: 17-methyl-(5α)-androstano[3,2-d]isoxazol-17β-ol；17α-Methyl-5α-androstanol-(17β)-<3.2-c>-isoxazol；17β-Hydroxy-17α-methyl-androstano<3.2-c>isoxazol；17β-Hydroxy-17α-methyl-androstan<3.2-c>isoxazol；(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6-oxa-7-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4,7-dien-17-ol
• CAS: 360-66-7
• 化学式: C₂₁H₃₁NO₂
• 分子量: 329.483
• InChiKey: NSYTUNFHWYMMHU-IYRCEVNGSA-N

物化性质

• 熔点：
  169-170°
• 比旋光度：
  D +19°
• 沸点：
  458.0±45.0 °C(Predicted)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  雄异恶唑 在 盐酸 作用下， 以 乙醚 、 溶剂黄146 为溶剂， 反应 0.12h， 生成 17,17-dimethyl-(5α)-18-nor-androst-13-eno[3,2-d]isoxazole
  参考文献：
  名称：

  甾体杂环。七。雄甾烷（2,3-D）异恶唑及相关化合物。

  摘要：

  DOI：

  10.1021/jm00337a001
• 作为产物：
  描述：

  羟甲烯龙 在 羟胺乙酸盐 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 雄异恶唑
  参考文献：
  名称：

  de Ruggieri,P. et al., Gazzetta Chimica Italiana, 1962, vol. 92, p. 768 - 798

  摘要：

  DOI：

文献信息

• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Oral pharmaceutical compositions containing cyclodextrins as taste masking agent
  申请人：——

  公开号：US20040115258A1

  公开（公告）日：2004-06-17

  The application discloses oral pharmaceutical compositions which are tasted in the mouth during administration. Fast-dissolving tablets, chewable tablets and effervescent dispersions are exemplified. To mask the taste of unpleasant-tasting active ingredients, it has been found that blending with cyclodextrin without the conventional complex formation is effective. Consequently more economical modes of manufacture such as simple granulation and dry blending can be used.

  该申请揭示了口服制剂，其在给药过程中在口腔中被品尝。快速溶解片剂、可咀嚼片剂和泡腾分散剂是示例。为了掩盖令人不愉快的活性成分的味道，发现与β-环糊精混合而无需传统的复合形成是有效的。因此，可以使用更经济的制造方式，如简单的制粒和干混合。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Ripple Therapeutics Corporation

  公开号：US20210347809A1

  公开（公告）日：2021-11-11

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本文描述了可加工的组合物，其中至少包含一个可在其自由形式下加工的成分。本文还描述了用于治疗眼部疾病或障碍的组合物和方法，包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞。所述组合物和方法包括表现出抗炎活性、降低眼内压力（IOP）和/或其他理想活性的类固醇和前列腺素。将所述组合物注射到眼中可为患有眼部障碍的患者提供治疗益处。
• Identification of steroid isoxazole isomers marketed as designer supplement
  作者：Maria K. Parr、Michael Gütschow、Jörg Daniels、Georg Opfermann、Mario Thevis、Wilhelm Schänzer

  DOI：10.1016/j.steroids.2008.11.006

  日期：2009.3

  The product Orastan-A from Gaspari Nutrition was analyzed for its steroid content. According to the labeling, it is supposed to contain "5a-Androstano[2,3-c]furazan-17b-tetrahydropyranol ether", also called furazadrol-THP ether. The GC-MS analyses of the liberated steroids (after extraction from the capsule matrix and cleavage of the THP ether, TMS-derivative and underivatized) revealed mass spectra

  分析了来自Gaspari Nutrition的产品Orastan-A的类固醇含量。根据标签，它应该包含“ 5a-Androstano [2,3-c] furazan-17b-四氢吡喃醚”，也称为呋喃唑醇-THP醚。所释放的类固醇的GC-MS分析（从胶囊基质中提取并裂解THP醚，TMS衍生物和未衍生的THP醚后）显示出两种成分的质谱，均与标记不一致。因此，类固醇通过质谱，核磁共振波谱和X射线晶体结构分析等不同的分析技术进行表征。它们被鉴定为17β-羟基雄甾烷[3,2-c]异恶唑和-[2,3-d]异恶唑。